Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.9B
447M shares
52-week range
$1.67 – $5.63
64% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.2M | $164.1M | $263.5M |
| Cost of revenue | $956.0K | $8.1M | $0 | $0 | $0 | $10.8M | $124.0M | $7.3M |
| Gross profit | −$956.0K | −$8.1M | $0 | $0 | $0 | −$9.6M | $40.1M | $256.2M |
| Gross margin | — | — | — | — | — | -804.5% | 24.4% | 97.2% |
| R&D | $99.8M | $166.0M | $201.7M | $259.0M | $294.8M | $344.1M | $282.3M | $300.3M |
| Operating income | −$128.3M | −$206.9M | −$261.9M | −$342.7M | −$398.9M | −$460.6M | −$395.3M | −$403.4M |
| EBITDA | −$122.6M | −$189.4M | −$260.8M | −$328.3M | −$371.8M | −$414.4M | −$331.4M | −$357.1M |
| Net income | −$123.6M | −$197.6M | −$259.6M | −$342.3M | −$395.9M | −$444.0M | −$372.2M | −$391.0M |
| Net margin | — | — | — | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (diluted) | -1.27 | -1.50 | -1.88 | -2.23 | -2.49 | -1.89 | -1.28 | -1.09 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $362M | $-0.55 | $-0.64–$-0.35 | 6 |
| 2027 | $496M | $-0.31 | $-0.36–$-0.24 | 6 |
| 2028 | $740M | $0.00 | $-0.01–$0.01 | 5 |
| 2029 | $987M | $0.21 | $0.20–$0.23 | 1 |
Forward consensus · source: Financial Modeling Prep
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
www.iovance.comNo one on the platform currently holds IOVA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 651,000 | $1.8M |
No one on the platform has traded IOVA yet.
| $667M |
| — |
| ERASErasca, Inc. | $18.29 | +14.24% | $5.7B | — |
| MBXMBX Biosciences, Inc. Common Stock | $53.85 | +2.94% | $1.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
$IOVA Iovance Biotherapeutics has gained momentum with a 9.4% share increase following the conditional approval of its melanoma therapy, Amtagvi, in Australia. Analysts maintain a bullish outlook, with strong revenue growth despite profitability challenges.
View on StockTwits ↗$IOVA Currently sitting at 446.5 million on Marketwatch. Just wondering if $3.93 is the SP in coming days.
View on StockTwits ↗$IOVA ASCO ICYMI: @FunchainMD and @DrBetofMDPhD of @StanfordCancer highlight practice-changing studies in immunotherapy from #ASCO26 on a new episode of the #ASCODailyNews Podcast: https://bit.ly/4wcst8i https://x.com/ASCO/status/2071670119734927777?s=20
View on StockTwits ↗$IOVA so Wayne sold his other company today. Will he bring that money here?
View on StockTwits ↗$IOVA I am searching for a stock that didn't participate in the beautiful broad rally that touched all indices today. It didn't take long to find one lol. And the loser is.....IOVA, yet again! I know there's only a few on this board that understands dilution is awful so I am sure no one cares about having their shares and money stolen from them. Keep up the great work Fred and your puppet CFO. You get an A+ in knowing the art of dilution.
View on StockTwits ↗$IOVA long 109500 shares I like my position. Earnings will surprise in my opinion.
View on StockTwits ↗$IOVA hear this one: 14 years in remission after stage 4 metastatic melanoma… the guy underwent TIL therapy trial at NIH in 2012🫡 https://www.facebook.com/share/p/1c8QWjisEn/
View on StockTwits ↗$IOVA held higher lows ✔️ 3 consecutive higher high✔️ That looks like a possible upwards trend! The fact price holding bottom line trajectory and grinding shows this is going to be a slow climb but if current pivot point 3.81 is infact our pivot into hill 2 build tomorrow could be the last day we trade in the 4.20’s as and cement the 4.33 our official support. Or we break on last day of quarter close and go towards 4.05
View on StockTwits ↗$IOVA I guess I shouldn't complain about Fred anymore, after watching the continuing shetshow that is my SMCI stock.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.